Chronic Kidney Disease & Non-alcoholic Fatty Liver Diseases

Status Completed

Clinical Trial Summary

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with metabolic syndrome, obesity, and type II diabetes. NAFLD is considered to be an independent risk factor for cardiovascular disease and there is accumulating evidence to support a causative role in the development of chronic kidney disease (CKD). So, we aim first to assess the prevalence of chronic kidney disease in NAFLD patients, secondly to detect the association between hepatic fibrosis and CKD in NAFLD patients

Clinical Trial Description

This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A control group of 30 healthy volunteers who looks normal on ultrasonography from February 2021 to July 2021. Methods: All included patients will be subjected to: 1. Detailed history, complete general and systemic examination . 2. BMI will be calculated as follow 3. Abdominal Ultrasonography. 4. Laboratory investigations: Fasting and post-prandial blood sugar Serum lipogram. Liver function tests. Serum creatinine, Albumin -creatinine Ratio. 5. Calculation of estimated Glomerular Filtration Rate eGFR. 6. Liver stiffness measurements to detect degree of fibrosis and measurement of the degree of steatosis using (Fibroscan) Ethical considerations: The study will be approved by The Ethical committee of Sohag Faculty of Medicine, Sohag University. The study protocol will be adherent to practice guidelines of the World Medical Association Code of Ethics (Declaration of Helsinki). After explanation about the nature of the procedures, possible complications, benefits, and steps of the study, All patients will give a written informed consent for participating in the study, performing abdominal ultrasound, taking blood samples, performing fibroscan. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04779905
Study type	Observational
Source	Sohag University
Contact
Status	Completed
Phase
Start date	February 28, 2021
Completion date	September 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06386172` - Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm	N/A
Recruiting	`NCT04910867` - APOL1 Genetic Testing Program for Living Donors	N/A
Completed	`NCT03434145` - Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases	N/A
Recruiting	`NCT04984226` - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD	Phase 2
Active, not recruiting	`NCT05887817` - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)	Phase 4
Recruiting	`NCT05318196` - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Terminated	`NCT05022329` - COVID-19 Vaccine Boosters in Patients With CKD	Phase 2/Phase 3
Not yet recruiting	`NCT04925661` - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia	Phase 1
Recruiting	`NCT04961164` - Resistant Starch Prebiotic Effects in Chronic Kidney Disease	N/A
Completed	`NCT05015647` - Low Protein Diet in CKD Patients at Risk of Malnutrition	N/A
Completed	`NCT03426787` - Helping Empower Liver and Kidney Patients	N/A
Recruiting	`NCT06094231` - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study	N/A
Completed	`NCT04363554` - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease	N/A
Recruiting	`NCT04831021` - Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role?	N/A
Terminated	`NCT04877847` - Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury	N/A
Recruiting	`NCT04422652` - Combination of Novel Therapies for CKD Comorbid Depression	Phase 2
Completed	`NCT05055362` - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study	N/A
Not yet recruiting	`NCT06330480` - Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease	N/A
Recruiting	`NCT03176862` - Left Ventricular Fibrosis in Chronic Kidney Disease	N/A
Terminated	`NCT02539680` - Intestinal Phosphate Transporter Expression in CKD Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases — NAFLD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms